FDA: Pfizer Voluntarily Withdraws Cancer Treatment Mylotarg from
Pfizer Inc. today announced the voluntary withdrawal from the U.S.
market of the drug Mylotarg (gemtuzumab ozogamicin) for patients with
acute myeloid leukemia (AML), a bone marrow cancer. The company took the
action at the request of the U.S. Food and Drug Administration after
results from a recent clinical trial raised new concerns about the
product’s safety and the drug failed to demonstrate clinical benefit to
patients enrolled in trials.